Abstracts tagged "Cardiovascular"

Abstract Number: 0468 • ACR Convergence 2025
Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis (ERS-RA) in a nationwide multicenter Chinese cohort
Xingbei Dong¹, Nan Jiang², Hong Li³, Misti Paudel⁴, Jiangmei Liu⁵, Xinwang Duan⁶, Dongmei Wu⁷, Hongbin Li⁸, Fen Li⁹, Yongfu Wang¹⁰, Ju Liu¹¹, Shengqian Xu¹², Hui Luo¹³, huanzi dai¹⁴, Shuhong Chi¹⁵, Jian Xu¹⁶, Lijun Wu¹⁷, zhaohui zheng¹⁸, Jing Xue¹⁹, Xiaofu Yu²⁰, QIn Huang²¹, Xiaofei Shi²², Xiaomin Zhang²³, Yuehong Huo²⁴, Qian Wang², Xiaofeng Zeng²⁵, Daniel Solomon²⁶, Mengtao Li² and Xinping Tian², ¹Peking Union Medical College Hospital, Beijing, China (People's Republic), ²Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ³Beijing Anzhen Hospital, Capital Medical University, Beijing, China (People's Republic), ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Chinese Center for Disease Control and Prevention, Beijing, China (People's Republic), ⁶The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ⁷The People's Hospital of Yuxi City, Yuxi, China (People's Republic), ⁸The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ⁹The Second Xiangya Hospital of Central South University, Changsha, China (People's Republic), ¹⁰The First Affiliated Hospital of Baotou Medical College, Baotou, China (People's Republic), ¹¹Affiliated Jiujiang Hospital of Nanchang University, Jiujiang, China (People's Republic), ¹²The First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic), ¹³Xiangya Hospital of Central South University, Changsha, China (People's Republic), ¹⁴Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic), ¹⁵General Hospital of Ningxia Medical University, Yinchuan, China (People's Republic), ¹⁶The First Affiliated Hospital of Kunming Medical University, Kunming, China (People's Republic), ¹⁷People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China (People's Republic), ¹⁸Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic), ¹⁹The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic), ²⁰Guyuan People’s Hospital, Guyuan, China (People's Republic), ²¹Nanfang Hospital, Guangzhou, China (People's Republic), ²²The First Affiliated Hospital of Henan University of science and Technology, Luoyang, China (People's Republic), ²³Red Flag Hospital Affiliated to Mudanjiang Medical College, Mudanjiang, China (People's Republic), ²⁴The Fifth People's Hospital of Datong, Datong, China (People's Republic), ²⁵Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ²⁶Brigham and Women's Hospital, Newton, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing cardiovascular (CV) events compared to the general population. However, this risk is often…
Abstract Number: 0072 • ACR Convergence 2025
Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs
Chary López pedrera¹, Laura muñoz-Barrera², Rafaela Ortega-Castro³, Sagrario Corrales², Jerusalen Calvo Gutierrez⁴, Concepción Aranda Valera⁵, Lourdes Ladehesa⁶, Pilar Font⁷, Ismael Sanchez-Pareja², Elena Moreno-Caño⁵, M Carmen Abalos-Aguilera⁸, Christian Merlo-Ruiz⁸, MARIA ANGELES AGUIRRE ZAMORANO², Pedro Seguí-Azpilcueta⁹, Tomás Cerdó², Nuria Barbarroja¹⁰, Rocío González Conejero¹¹, Constantino Martínez¹¹, Carlos Pérez Sánchez¹² and Alejandro Escudero¹³, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Sevilla, Spain, ⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁶IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Servicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB Pascual Parrilla., Murcia, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain
Background/Purpose: Therapeutic advances in RA have introduced effective treatments, including b/tsDMARDs such as Baricitinib. However, its cardiovascular safety profile remains unclear, partly due to the…
Abstract Number: 2608 • ACR Convergence 2025
Metabolic dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiac Manifestations in Psoriasis
Maria Dons¹, Charlotte Näslund-Koch², Morten Sengeløv³, Sofie Bøgh-Sørensen³, Kristoffer Skaarup³, Marianne Bengtson Løvendorf⁴, Filip Davidovski³, Anne Marie Reimer Jensen³, Brittany Weber⁵, Lise Lotte Gluud⁶, Claus Zachariae², Lone Skov² and Tor Biering-Sørensen³, ¹Copenhagen University Hospital Gentofte, Copenhagen, Hovedstaden, Denmark, ²Dep. of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, ³Center for Translational Cardiology and Pragmatic Randomized Trials, Dep. of Cardiology, Copenhagen University Hospital - Gentofte, Copenhagen, Hovedstaden, Denmark, ⁴Department of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, ⁵Brigham and Women's Hospital, DEDHAM, MA, ⁶Gastro Unit, Copenhagen University Hospital – Hvidovre, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a cardiometabolic risk factor. Individuals with psoriasis have a high prevalence of MASLD, yet…
Abstract Number: 2256 • ACR Convergence 2025
Improved Outcomes of Acute Myocardial Infarction Among Patients with Rheumatoid Arthritis: A Propensity Matched National Study
Qurat Ul Ain¹ and MIrza faris Ali Baig², ¹Medstar Georgetown University Hospital, Arlington, VA, ²Medstar Health, Arlington, VA
Background/Purpose: The increased risk of cardiovascular morbidity and mortality with rheumatoid arthritis has been increasingly acknowledged over the past decades. Cardiovascular disease risk management for…
Abstract Number: 1745 • ACR Convergence 2025
High Emotional Distress Predicts Suboptimal Cardiovascular Health Among Patients with Juvenile-Onset Lupus and Dermatomyositis: Longitudinal Analysis of the Lupus Erythematosus and Dermatomyositis Stress and Cardiovascular Health Cohort Study
Kaveh Ardalan¹, Angel Davalos¹, Hwanhee Hong¹, Bryce Reeve¹, Christoph Hornik¹, M. Anthony Moody¹, Donald Lloyd-Jones², Eveline Wu³, Audrey Ward⁴, Simisola Gbadegesin⁵, Rebecca Sadun⁶, Jeffrey Dvergsten⁷, Lauren Covert¹, Ann Reed¹, Mark Connelly⁸ and Laura Schanberg⁹, ¹Duke University School of Medicine, Durham, NC, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³UNC Chapel Hill, Chapel Hill, NC, ⁴Children's National Hospital, Washington, DC, ⁵Wake Forest University School of Medicine, Winston-Salem, NC, ⁶Duke University, Durham, NC, ⁷Duke University Hospital, Hillsborough, NC, ⁸Children’s Mercy Kansas City/University of Missouri-Kansas City School of Medicine, Kansas City, MO, ⁹Duke University Medical Center, DURHAM, NC
Background/Purpose: Juvenile lupus & dermatomyositis (JSLE/JDM) patients experience high emotional distress and premature loss of cardiovascular health (CVH), defined as protective factors against cardiovascular disease…
Abstract Number: 1398 • ACR Convergence 2025
Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health
R. Mohamad Javier¹, Bernadus Bramantyo², Arkan Berlian³, Mahardika Nugraha⁴, Azzura Simanulang¹, Eko Setyo Herwanto⁵, Athaya Febriantyo Purnomo⁶, Jonathan Jonathan⁷, Ananingati Ananingati⁵, Budi Prakoso⁸ and Aisyah Rizki Nirmala Hanum⁵, ¹University of Indonesia Hospital, Jakarta Selatan, Jakarta Raya, Indonesia, ²Sardjito General Hospital, Daerah Istimewa Yogyakarta, Yogyakarta, Indonesia, ³Dr. Cipto Mangunkusumo Hospital, Jakarta Barat, Jakarta Raya, Indonesia, ⁴Universitas Islam Sultan Agung, KOTA SEMARANG, Jawa Tengah, Indonesia, ⁵Universitas Muhammadiyah Malang, Malang, Jawa Timur, Indonesia, ⁶Saiful Anwar General Hospita, Malang, Jawa Timur, Indonesia, ⁷RSUD Kalideres, Jakarta, Jakarta Raya, Indonesia, ⁸Department of Internal Medicine, RST dr Soepraoen, Malang, Jawa Timur, Indonesia
Background/Purpose: Autoimmune rheumatic diseases such as Sjögren’s Syndrome (SS) and Systemic Sclerosis (SSc) can significantly impact reproductive health and increase maternal cardiovascular risk. These conditions…
Abstract Number: 0681 • ACR Convergence 2025
Evaluation of Serial Cardiovascular Magnetic Resonance Monitoring and Immunosuppressive Therapy in Predicting Long-Term Outcomes in Systemic Sclerosis
Aïcha Kante¹, Sandra Mghaieth², bertrand Dunogue³, Alice berezne³, Cloé Comarmond¹, Marie-Pierre Revel², Guillaume Chassagnon², Luc Mouthon³ and Benjamin Chaigne³, ¹Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ²Radiology Department, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease that can manifest as widespread skin and visceral fibrosis, potentially affecting major organs including the heart.…
Abstract Number: 0458 • ACR Convergence 2025
TyG-BMI Index as a Serological Biomarker for Carotid Plaque and Cardiac Function Changes in Rheumatoid Arthritis
Rebeca L. Polina-Lugo¹, Oscar Azael Garza-Flores², Fernanda M. Garcia-Garcia³, Esteban C. Garza-Gonzalez⁴, Jesus Alberto Cardenas-de la Garza⁵, Iris J. Colunga-Pedraza³, Jose R Azpiri-Lopez⁶, Dionicio A. Galarza-Delgado³, Victor M Fraga-Enriquez⁷ and Diego Azamat Salcedo Almanza⁸, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁶Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁷Cardiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁸Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: The Triglyceride-Glucose-BMI index (TyG-BMI) is a reliable method for detecting insulin resistance (IR), with effectiveness comparable to the gold standard. Elevated TyG-BMI levels have…
Abstract Number: 0045 • ACR Convergence 2025
Genetic regulators of corticosteroid response in hepatic and adipose tissue and risk of adverse metabolic outcomes in patients with rheumatoid arthritis initiating glucocorticoids.
Thomas Riley¹, Bryant England², Austin Wheeler², Punyasha Roul³, Grant Cannon⁴, Brian Sauer⁵, Gary Kunkel⁶, Katherine Wysham⁷, Beth Wallace⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Mitchell Lazar¹, Wenxiang Hu¹⁴, Michael Levin¹⁵, Scott Damrauer¹⁵, Rui Xiao¹⁶, Tate Johnson², Ted Mikuls², Joshua Baker¹ and Michael George¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴Guangzhou National Laboratory, Guangzhou, China (People's Republic), ¹⁵University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ¹⁶Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Previous studies identified single nucleotide polymorphisms (SNPs) that affect hepatocyte and adipocyte response to glucocorticoids (GCs). We aimed to determine if these candidate SNPs…
Abstract Number: 2585 • ACR Convergence 2025
The effect of prophylactic colchicine use on gene expression in gout
Austin Wheeler¹, Guanqi Lu², Ana Vazquez³, Jeffrey Edberg⁴, Angelo Gaffo⁵, Tate Johnson¹, Michael Duryee¹, James O'Dell¹, Jeff Newcomb¹, Michael Pillinger⁶, Robert Terkeltaub⁷, Ryan Ferguson⁸, Mary Brophy⁸, Tuhina Neogi⁹, Bryant England¹, Ted Mikuls¹, Tony Merriman¹⁰ and Richard Reynolds⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²Michigan State University, East Lansing, MI, ³Michigan State University, Miami, FL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ⁶New York University Grossman School of Medicine, New York,, NY, ⁷Retired, San Diego, CA, ⁸VA Cooperative Studies Program Coordinating Center, Boston, MA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Colchicine is recommended for the treatment and prophylaxis of gout flares and approved for secondary prevention of ischemic cardiovascular disease (CVD). While its primary…
Abstract Number: 2245 • ACR Convergence 2025
Add-on of Coronary Artery Calcium Score Significantly Improves the Risk Prediction of Cardiovascular Diseases in Patients with Rheumatoid Arthritis: From a Real-world Cohort Study
Yao-Wei Zou, Ying Yang, Zhi-Ming Ouyang, Ran Shi, Tao Wu, Kui-Min Yang, Jian-Da Ma and Lie Dai, Department of Rheumatology and Immunology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China (People's Republic)
Background/Purpose: Cardiovascular diseases (CVD) are the first cause of death in patients with rheumatoid arthritis (RA). The guidelines recommend risk prediction in all RA patients.…
Abstract Number: 1743 • ACR Convergence 2025
Comparative assessment of cardiovascular risk and its predictors in a large cohort of young adults with juvenile systemic lupus erythematosus and juvenile dermatomyositis
Jiangning Li, Shreya Doddi, Tharuni Mailoo and Coziana Ciurtin, University College London, London, United Kingdom
Background/Purpose: Juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM) are associated with chronic inflammation that can accelerate atherosclerosis. There is no specific guidance regarding…
Abstract Number: 1397 • ACR Convergence 2025
Cardiovascular And Cerebrovascular Risk In Sjögren’s Disease: Results From A Prospective Multicenter Cohort.
Olga Rusinovich¹, Zulema Plaza², Monica Fernandez Castro³, Jose Rosas Gómez de Salazar⁴, Victor Martinez-Taboada⁵, Alex Olive⁶, Raúl Menor Almagro⁷, Belén Serrano-Benavente⁸, Judit Font-Urgelles⁹, Angel Garcia-Aparicio¹⁰, Sara Manrique-Arija¹¹, Jesús Alberto Garcia Vadillo¹², Ruth Lopez-Gonzalez¹³, Javier Narváez¹⁴, Maria Beatriz Rodriguez¹⁵, Carlos Galisteo¹⁶, Jorge Juan Gonzalez Martin¹⁷, Paloma Vela Casasempere¹⁸, Cristina Bohorquez¹⁹, MARIA CELIA ERAUSQUIN ARRUABARRENA²⁰, Beatriz Paredes-Romero²¹, Leyre Riancho-Zarrabeitia²², Sheila Melchor Diaz²³, José María Pego-Reigosa²⁴, Sergi Herdia²⁵, Clara Moriano²⁶, Mª Angeles Blazquez Cañamero²⁷, Paula Estrada-Alarcón²⁸, Enrique Judez²⁹, Nerea Alcorta-Lorenzo³⁰, Consuelo Ramos Giraldez³¹, Fernando Sánchez-Alonso³² and Jose Luis Andreu³³, ¹Puerta de Hierro University Hospital, Boadilla del Monte, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ³PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ⁴Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Solo practice, Barcelona, Spain, ⁷Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁸Hospital Gregorio Marañon, Madrid, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Hospital Universitario de Toledo, Toledo, Spain, ¹¹Hospital Regional Universitario Málaga, Malaga, Spain, ¹²Hospital Universitario La Princesa, Madrid, Spain, ¹³Zamora Health Complex, Salamanca, Spain, ¹⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁵Canarias University Hospital, La Laguna- Tenerife, Spain, ¹⁶Hospital Parc Taulí, Sabadel, Sabadel, Spain, ¹⁷HM Sanchinarro Univeristary Hospital, Madrid, Spain, ¹⁸Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁹La Paz University Hospital, Alcalá De Henares, Spain, ²⁰Dr Negrin University Hospital, Ls Palmas, Spain, ²¹Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ²²Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²³¹² de Octubre University Hospital, Madrid, Spain, ²⁴Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ²⁵Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁶Hospital León, LEON, Castilla y Leon, Spain, ²⁷Hospital Ramon y Cajal, Madrid, Spain, ²⁸Complex Universitari Hospital Moisès Broggi, Barcelona, Spain, ²⁹Albacete University Hospital, Albacete, Spain, ³⁰Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ³¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ³²Sociedad Española de Reumatología, Madrid, Spain, ³³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: To evaluate the incidence of cardiovascular and cerebrovascular events (CVEs) in patients with Sjögren’s Disease (SjD), focusing on major adverse cardiovascular events (MACE), defined…
Abstract Number: 0677 • ACR Convergence 2025
Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.
Jessica Fairley¹, Elizabeth Paratz², Dylan Hansen³, Susanna Proudman⁴, Joanne Sahhar⁵, Gene-Siew Ngian⁶, Diane Apostolopoulos⁶, Jennifer Walker⁷, Lauren Host⁸, Wendy Stevens¹, Andre La Gerche², Mandana Nikpour⁹ and Laura Ross¹, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ³St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Monash Health, Melbourne, Victoria, Australia, ⁶Monash University, Melbourne, Victoria, Australia, ⁷Flinders University, Adelaide, Victoria, Australia, ⁸Fiona Stanley Hospital, Perth, Victoria, Australia, ⁹University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia
Background/Purpose: The incidence of sudden cardiac death (SCD) is suspected to be increased in systemic sclerosis (SSc). However, data describing SCD incidence in SSc are…
Abstract Number: 0450 • ACR Convergence 2025
The Fibrosis-4 Index (FIB-4) Correlates with Cardiovascular Risk and Insulin Resistance in Patients with Rheumatoid Arthritis
Jose Marí Viotti-Serra¹, Elena Heras-Recuero², Juan C. Quevedo-Abeledo³, Miguel A. González-Gay⁴ and Ivan Ferraz Amaro⁵, ¹Hospital Universitario de Canarias, Tenerife, Canarias, Spain, ²Fundación Jiménez Díaz, Madrid, Madrid, Spain, ³Hospital Doctor Negrín, Las Palmas de Gran Canaria, Canarias, Spain, ⁴Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, ⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: The Fibrosis-4 index (FIB-4), a non-invasive tool for assessing liver fibrosis, has been linked to cardiovascular (CV) risk in the general population. This is…

« Previous Page
1
…
4
5
6
7
8
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].